Sirolimus-Eluting Stents May Be Best for Bifurcation Lesions
Long-term outcomes are significantly better than those associated with paclitaxel-eluting stents
MONDAY, March 22 (HealthDay News) -- In patients with bifurcation lesions, treatment with sirolimus-eluting stents is associated with better long-term outcomes than treatment with paclitaxel-eluting stents, according to a study published online March 17 in the Journal of the American College of Cardiology.
Young Bin Song, M.D., of the Sungkyunkwan University School of Medicine in Seoul, South Korea, and colleagues compared outcomes in 1,033 patients with bifurcation lesions treated with sirolimus-eluting stents and 562 patients treated with paclitaxel-eluting stents.
After a median follow-up of 22 months, the researchers found that patients treated with sirolimus-eluting stents had a lower incidence of major adverse cardiac events and target lesion revascularization than patients treated with paclitaxel-eluting stents (hazard ratios, 0.53 and 0.55, respectively) but not of cardiac death and cardiac death or myocardial infarction (hazard ratios, 2.77 and 0.97, respectively).
"Patients with paclitaxel-eluting stents have shown comparable clinical outcomes to those with sirolimus-eluting stents in several studies, but the latter drug-eluting stent may be superior to the former in complex lesion subsets," the authors write. "Considering the complexity of bifurcation lesions, our results that sirolimus-eluting stents decrease adverse outcomes seem to be relevant."